Maynard Um
-
-
-
-
-
-
-
Canaccord Reiterates Hold Rating on Vertex (VRTX)
-
-
-
-
-
-
-
Vertex gets FDA acceptance for IgA nephropathy drug application
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $572 at Bernstein SocGen Group
-
-
-
-
-
-
-
Halozyme licenses drug delivery technology to Vertex for $15 million
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $525 at Truist Securities
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $600 at Oppenheimer
-
-
-
-
-
-
-
Oppenheimer Upgrades Vertex (VRTX) to Outperform
-
418,486 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

